Literature DB >> 9686935

Effect of long-term administration of duloxetine on the function of serotonin and noradrenaline terminals in the rat brain.

L E Rueter1, K Kasamo, C de Montigny, P Blier.   

Abstract

Duloxetine, an inhibitor of both 5-hydroxytryptamine (5-HT) and noradrenaline (NA) reuptake processes, has been developed as a potential antidepressant drug. The present study was initiated to investigate the functioning of multiple components of the 5-HT and NA systems following the long-term administration of duloxetine. In rats treated for 21 days with duloxetine (20 mg/kg/day), the recovery times of dorsal hippocampus CA3 pyramidal neurons from microiontophoretic applications of 5-HT and NA were significantly increased, indicating ongoing reuptake blockade with the minipump in place delivering the drug. The remaining experiments were performed following a 48-h washout. Electrically evoked release of [3H]5-HT from preloaded slices was enhanced in the midbrain, presumably due to a desensitization of the somatodendritic 5-HT1D and 5-HT1A autoreceptors. In addition, evoked release of [3H]5-HT was increased in the hippocampus, which could have been due to the desensitization of the alpha2-adrenergic heteroreceptors located on the 5-HT terminals. In contrast, there was no change in the evoked release of [3H]5-HT in the frontal cortex despite decreased functioning of the 5-HT transporter found in this brain region. Similar to changes in 5-HT release, electrically evoked release of [3H]NA was enhanced in the hippocampus and frontal cortex of rats treated chronically with duloxetine. These increases in [3H]NA release were most likely due to the desensitization of the alpha2-adrenergic autoreceptor in the hippocampus and to the desensitization of the NA transporter in the frontal cortex, respectively. These data suggest that long-term administration of duloxetine is able to induce changes in the 5-HT and NA systems that lead to enhanced release of both 5-HT and NA in some limbic brain areas. Duloxetine, therefore, may be a useful antidepressant compound.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9686935     DOI: 10.1007/pl00005214

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  5 in total

1.  Duloxetine: a new pharmacologic therapy for stress urinary incontinence.

Authors:  Victor W Nitti
Journal:  Rev Urol       Date:  2004

2.  Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise.

Authors:  David M Marks; Manan J Shah; Ashwin A Patkar; Prakash S Masand; Geun-Young Park; Chi-Un Pae
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

3.  Brain region-specific effects of short-term treatment with duloxetine, venlafaxine, milnacipran and sertraline on monoamine metabolism in rats.

Authors:  Katsumasa Muneoka; Yukihiko Shirayama; Morikuni Takigawa; Seiji Shioda
Journal:  Neurochem Res       Date:  2008-08-27       Impact factor: 3.996

4.  Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance.

Authors:  Matteo Martino; Giulio Rocchi; Andrea Escelsior; Michele Fornaro
Journal:  Curr Neuropharmacol       Date:  2012-06       Impact factor: 7.363

5.  Study of Sex Differences in Duloxetine Efficacy for Depression in Transgenic Mouse Models.

Authors:  Yong Xu; Lei Ma; Wei Jiang; Yuhong Li; Gang Wang; Rena Li
Journal:  Front Cell Neurosci       Date:  2017-10-31       Impact factor: 5.505

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.